great We the I will afternoon. moment the starkly to find accomplish is knew in ourselves world one imagined few for scale, challenge we possible Good Agnes. possible. opportunity and extraordinary but months things incredible different broadest industry you, of on than the It a also a challenge healthcare Thank believe short the of sciences a tools and the sector. one ago. faster overall life much rise we than we
For of alike, the and X/XX. sciences healthcare, this is life pandemic equivalent public diagnostics companies health
with and benefit the tools new we deployment a make realization a we to new and a that to scale investment, on forward current biotechnology step for global need as all of emerging, huge is there it, Even crisis, manage in rush is mankind. the development paradigm dawning a of
we to do together amazing safety. understanding believe and we surveillance, development. and system things And we of proteomic pandemics. will monitoring data global response as be as therapeutic term will as can rapidly a that crisis, integrated to longer-term an with in tools of address partnership community, Working tools vaccine and immune important strong as current immune role, the and pathogen support long immune are to and throughput, future system a threats. a genomic well higher deploy stockpiles for facets collaboration research Furthermore, faster deploy governments of that the fight view governments the resolute demand we is foundational response and have We essential public bodies flexibility, that point future near-term that new horizon, of health public-private play the that both in enable new Fluidigm and national to all networks that in an monitoring believe tools will and preparing
enable institutions global and And and and human we starting are products, detection growing multiple expertise Our research A of the in health. for virus pivoted fight COVID-XX Fluidigm with to pandemic. against the engaging number in profiling immune governments and the scientific on technologies medical QX, frontiers community important unprecedented support of testing.
our capabilities and the surprise technology remain mass global at to extraordinary serving needs that of research forefront of this of we it Given the no are scores diseases. We platforms, across microfluidics, cytometry powerful effort. two is committed
a However, in products term, for the are COVID-XX near manner our needs. we cohesive core address reconfiguring to
place right focused Our right powering us time, puts discovery opportunities. deployment right the at innovative technology biomarker on in the the and
QX. a backlog. to Shifting good and with a pipeline the strong began in position We year
As simple the daily sustained Asia, moved executive first themes. holding organize swiftly a to meetings in COVID-XX cases aligned we response, emerged around three
the half around for pleased level. U.K. employees, to Paris, the than confirmed is into San a our of checks a and on Toronto, and foremost, we to our performing cascaded procedures in We manufacturing safety. staff, remote in wipe report protective high from all sent Francisco, posture, masks distancing focused outsiders, Later, of the and supplies this no have social moving world I'm of employee employees, our Tokyo our model Singaporean down and our team built stockpiles of implementing facility and safety. general moved at more facility organization environments locking First had Chinese we temperature we employees, infections to down work
activities organized customer-facing new way. we Second, in a
constructed engineers service our our their Asia Europe in COVID-related with mid-March, customized into As propositions, our refocused field two March, tools operations we pathogen along selectively testing our North by shut late the enhanced for America solutions followed value operational customers down quickly New existing and reconfiguring our teams Chinese Year, sent facilities and February, around immune in vectors: PPE. additional needs. business Internally, marketing with monitoring. early We first in R&D
pathogen testing, suited. well For microfluidics platform is uniquely our
the FDA for into began guidance authorization, centers, customer systems testing for Biomark we As new use U.S. us. emergency Juno and segments issued deploying
IFC process than Biomark-Juno our combination bulk as tests per as many more per single RNA utilizing million can XXX.XX two or X,XXX One detection year. tests day,
incremental for than impact the automated from with Our miniaturization and reagent We an less procedures technology labs interaction. these the numbers. requires we worked to was our human microfluidic placement historic instrument X,XXXx have configure other platforms. that of revenue In XX-well And the need QX, approach reduces extraction workflows. complete to format placements
lack this early pleased segment, awareness success. in channel brand of we've our and Given been customer with this
to Our assay of purchase value sample reagents numerous early lab-specific systems. compelled conservation We these to and with collaborated EUA submissions. submit high flexibility, labs adopters proposition, throughput
or Many social in To Oklahoma a of the other pipeline program the I'm will EUA University more and believe competitiveness help burden of impact these on we customers, partially growing with particularly customer working on submission Biomark-based our System reduce shutdowns press on Healthcare opportunities of work mitigate close are on our our collaborations this feeds proud in testing We record this lab increase in in our pace. statewide have releases. a website, at that quarter. segments. been shared and the a deploying
second system in that and submission year and of the assays additional will of EUA pipeline this needs initial a development leverage in address testing the half beyond. have We
immune monitoring, tool COVID-related our cytometry for is mass excellent For platform programs. an
data. custom geographically large deployment Most required side, assay by and from allows to large assay, cohorts. panels. the immune to new diverse biomarker in impactful, suspension best develop enabled investigational Profiling reagent cell profiling amazing the samples our panels, large biology, assess linked COVID-infected of of panels the questions. to a provides strategies from tool antibodies providing consortia response providing On multi-site system in robust our vaccine for new we simple COVID-related Maxpar and a an same combine databases, useful our This new released for design researchers immune Direct XXXX population, studies base kits We've our in therapy integrating supporting rapidly product catalog panel to common backbone the with built recently flexibility reproducibility a format. have that metals provides added Working Immune
our using ways. imaging in cytometry are groups Other new mass
researchers consortia are have and COVID tissue School on to Yale the Medicine the virus of organs. analyzing around from of already critical insights the lung impact are mass at instance, detailing Programs the and in formed papers understand an there at the cytometry. pace, For COVID-related world gleaned immune response incredible five
as our social a in this customers as benefit fast emerge, can with feeds mobilize as stories as so these common threat. we against single everyone they community sharing are We
immediate response. ties described our I've Everything to
infection a create program that thousands ECHO have additional rapid changer by by products a DARPA. system powered The development, game platform samples the we while program potential could including post a with host measuring conventional day ECHO and will However, or a being funded of program per detection process of microfluidics the The cell exposure ECHO in called Mount real-time PCR is much solutions. Department serological Defense. of RNA Icahn test potentially Sinai's antibody-based or of collaboration Medicine sooner infection, giving School evidence than
updates submission become as give including they will availability. EUA commercial We and available, on dates
we with robust final this the novel validation decision lines, time scientific deployment Our balancing will all the partners importance and on approach. make speed of of recognize
during no his of oriented stones management. color we're as Vikram short, will third preserve on section. downturn. cash provide been cash the sharp daily industry in The discussion has leaving ample we unturned area In
However, stronger every business overemphasize emerge believe work core We the day. the our even I thesis cash back single management is community quarters. we activities to and organization we will as discuss an coming that gets cannot intact, research in
the made legal term health near-term We we DARPA-related as trajectory, trade-offs and research such from sponsored settlements have groups, fundamentally are COVID from business our and work. compromising funding to preserve longer without benefiting
As system endeavors I market, XXXX, results immunome QX want term ever. The potential transition related these the in I for reinforce on one to analysis of last and is our tools of and more the impacts the views than our comprehensive to immune point. a viable to discussion
been our the before most our on oncology part Over has is immune questions accelerating to and system infectious today. few of business and immunome related disease But was linked last years, of focus disorders.
of XX% mass publications disease. are our cytometry infectious to Roughly related
we a is the infectious we can our remain For COVID or are could and impact of response. upward additional programs. pandemic committed core complementary work oncology unique of disease going other of oriented modest on essence, areas, In support therapeutic provided a offerings. We the that rapidly, expand most the anticipate infectious Fluidigm, on our disease but menu market heels for tying We together to COVID that with endeavors. believe to our portfolio catalyst and business this prior microfluidics to the they symbiotic vertical into accelerate
slower entered We business, to QX with pronounced down depend working Customer closed either to saw operations commentary, on not have or at a be research segments the a academic customer of impact hold out negative shut the we global community activities the will available. been Rounding a our on our normal community, March. XX% by when research what projects of will and approximately as XX% new middle returns most canceled. put budgets pace. but on Basic
we other online. near-term We anticipate closures funnel remains analytical instrument to been similar And Our placements, companies. heard COVID to that renovations delays for unit have facility have commentary and a built or we from sharp facility in backlog systems gating in deceleration items not due instrument related work. strong, putting
organizations motions selling feet once that get budgets the We've their will year. to from and who intact in and orders marketing We home believe later working on back reach are offices. flow, customers are adapted
we to normal consumables, are that run, labs anxious backlogs and to many of samples major of For to they our operations. have return core know
map accelerated commentary. of road merits we As response, part important strategy COVID-XX additional another that on comprehensive program our our
imaging many mass broad the menu staining, and incubated lab, panel or Therapeutic range announced elements commercial cytometry from antibody verification, of we acquisition and We are a the a offering. program QX. suspension-based services Fluidigm includes The experimental services Today, There to professional TIS. data design, call custom in this analysis. of conjugation launch Insights, sourcing, TIS and data
core their seeing operational run samples are to not labs We are or cannot demand from facilities. access immediate that
or cytometry capacity who related market capacity allowing services, backup constraints. addition, them concerns without provide we for testing In mass services for are to selling surge CROs
released panels could part commercially vehicle The TIS and not provides portfolio. a our new partner cytometry collaboration lab to but developing of innovations standard Fluidigm provides access become developed kit business that newly for institutions mass
by running new accelerate funding, instrument up or conduct it innovation, The data on can waiting market for projects. lab and of accounts generate especially studies. will disruption staffed For segments and the important fee-for-service light near-term believe the pandemic. pace they in our We is of technology open
our business, as are to and new has preparation pandemic on the well short-term we horizon. the In in the brought see as but about we are summary, role COVID-XX opportunities challenges we response incredibly excited playing
to review the turn now results. Vikram, I'll our call our complete a financial for over of CFO,
